The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Exelixis
A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Bruce Robinson
Consulting or Advisory Role - Eisai; Loxo
 
Candy Bermingham
No Relationships to Disclose
 
Soham Puvvada
No Relationships to Disclose
 
Anne E. Borgman
Employment - Exelixis
 
Monika K. Krzyzanowska
Honoraria - Eisai; Novartis
Consulting or Advisory Role - Eisai
Research Funding - Eisai (Inst); Exelixis (Inst); Ipsen (Inst)
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Exelixis; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer
 
Steven I. Sherman
Honoraria - Eisai; Genzyme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Genzyme; Ignyta; Loxo; Novartis; Novo Nordisk; Veracyte
Research Funding - Genzyme
Travel, Accommodations, Expenses - Eisai; Ignyta; Veracyte